Fig. 5From: A novel prognostic signature and therapy guidance for hepatocellular carcinoma based on STEAP familyTMB analysis, immunotherapy response, and therapeutic drug sensitivity prediction. A OncoPrint of frequently mutated genes in high- and low-risk groups. B TMB difference between high- and low-risk groups. C TIDE score between two groups. D chemotherapeutic drugs with significant IC50 differences between the two groupsBack to article page